Genetic variants influencing the emergence and progression of lung cancer

What is it about?

This comprehensive review critically explores the role of genetic variants in the initiation, development, and progression of lung cancer. The paper systematically compiles current findings from genome-wide association studies (GWAS), candidate gene analyses, and next-generation sequencing efforts that identify key single nucleotide polymorphisms (SNPs), mutations, and epigenetic modifications associated with lung carcinogenesis. It discusses the influence of inherited and somatic mutations in genes such as EGFR, KRAS, TP53, and ALK, among others, and how these alterations contribute to oncogenic pathways, tumor heterogeneity, drug resistance, and patient prognosis. By integrating findings across diverse populations and genetic backgrounds, the review emphasizes the potential for personalized medicine approaches in lung cancer diagnosis, risk prediction, and targeted therapy development. It also identifies gaps in current knowledge and suggests future directions for functional validation and clinical translation of these genetic insights.

Featured Image

Photo by Aakash Dhage on Unsplash

Photo by Aakash Dhage on Unsplash

Why is it important?

This paper is important because it provides a comprehensive overview of the genetic variants that contribute to the emergence and progression of lung cancer, offering critical insights into the molecular mechanisms underlying the disease. By synthesizing findings from genome-wide association studies, candidate gene analyses, and next-generation sequencing, the review highlights key mutations and polymorphisms that influence susceptibility, tumor behavior, and therapeutic response. This knowledge is essential for advancing precision medicine, as it enables the development of personalized strategies for early detection, risk assessment, and targeted treatment. Furthermore, the paper identifies current research gaps and guides future investigations toward novel biomarkers and drug development, ultimately contributing to improved clinical outcomes in lung cancer management.

Perspectives